杜氏肌营养不良症研究进展:从分子机制到治疗策略
Progress on Duchenne muscular dystrophy:from molecular mechanisms to therapeutic strategies
摘要
杜氏肌营养不良症(Duchenne muscular dystrophy,DMD)是最常见的致死性儿童神经肌肉遗传病,其发病源于抗肌萎缩蛋白(dystrophin)编码基因突变,导致肌膜稳定性受损,进而引发进行性肌肉萎缩与多器官功能衰竭.本文系统梳理了 DMD 的临床诊断体系、分子病理机制及前沿治疗策略,聚焦基因治疗领域的突破性进展,包括外显子跳跃、基因替代及基因组编辑等疗法的作用机制、临床证据及技术瓶颈,并结合最新研究成果展望了未来发展方向,以期为 DMD 的基础研究与临床转化提供全面参考.
Duchenne muscular dystrophy(DMD)is the most common lethal neuromuscular genetic disorder in children.It is caused by mutations in the DMD gene that abolish the expression of dystrophin,a protein essential for maintaining sarcolemmal integrity during muscle contraction.Its loss renders muscle fibers susceptible to contraction-induced injury,leading to progressive muscle degeneration and,ultimately,fatal cardiac and respiratory failure.In this review,we summarize the diagnostic framework,molecular pathogenesis,and current therapeutic strategies of DMD,with particular emphasis on the recent advances in gene therapy—namely the mechanisms,clinical evidence,and technical challenges of exon skipping,gene replacement,and genome editing.Drawing on the latest findings,we further outline the major challenges and future directions of the field,aiming to provide a comprehensive reference for both basic research and clinical translation.
年,卷(期):
2026, 48(10)
机标分类号:
R746.2
R318
R5
在线出版日期:
2026年10月29日